National Organization for Rare Disorders INC (Nord)

Based in DC

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $2.1M in lobbying spend across 38 quarterly filings, National Organization for Rare Disorders INC (Nord) is a significant lobbying presence. They deploy 17 individual lobbyists Their lobbying covers 7 issue areas. Active from 2018 to 2025.

$2.1M
Total Spend
8
Years Active
1
Firms Hired
17
Lobbyists Deployed
7
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$270K
2019$320K
2020$360K
2021$360K
2022$210K
2023$140K
2024$240K
2025$250K

Issues Lobbied

Health IssuesMedicare/MedicaidPharmacyBudget/AppropriationsCopyright/PatentImmigrationTaxation

Lobbying Firms

National Organization for Rare Disorders, INC. (Nord)

Lobbyists

Paul MelmeyerMelanie Swick BuzzelliPeter SaltonstallRachel SherRose Avellino GallagherTimothy BoydMichelle AdamsCorinne AlbertsHeidi RossRichard WhiteRuby DehkharghaniKarin HoelzerAllison HerrityHayley MasonMason BarrettSupraja SowmiyanarayanVictoria Gemme

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid, Pharmacy, Budget/Appropriations, Copyright/Patent and 2 more

  • •Bipartisan Health Care Stabilization Act
  • •Medicare Part D
  • •Right to Try Act; H.R.5247, S.204
  • •Rare disease Advancement, Research, and Education Act of 2018; H.R.5115
  • •National Institutes of Health Fundi
  • •Medicare Part D
  • •Right to Try Act; S.204
  • •Rare disease Advancement, Research, and Education Act of 2018; H.R.5115
  • •National Institutes of Health funding
  • •Food and Drug Administration Appropriations
  • •Orph
  • •Medicare Part D
  • •Step therapy in Medicare Advantage plans
  • •Restoring the Patient's Voice Act of 2017; H.R.2077
  • •Rare disease Advancement, Research, and Education Act of 2018; H.R.5115
  • •National Institut
  • •Medicare Part D
  • •Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and develop
  • •Medicare issues impacting patients with rare diseases.
  • •Medicare Part D.

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?
🏭 Pharma Lobbying
Industry overview and top spenders
🏭 Tech Lobbying
Industry overview and top spenders

Related Investigations

Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 22,000% ROI
When lobbying spending yields outsized returns.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.

Similar Clients

National Association of Benefits and Insurance Professionals
$8.6M total spend
F Hoffmann-la Roche LTD and its Affiliates
$4.0M total spend
Biotechnology Industry Organization
$2.8M total spend
The Campaign for Sustainable Rx Pricing
$2.6M total spend
Sanofi US Services INC (Formerly Known as Genzyme Corporation)
$2.0M total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.